GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq:GNVC) announced today that it has received a Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the company’s malaria vaccine program. This grant, valued at approximately $600,000 over two years, will be used to develop enhancements to the company’s vectors for vaccine applications against malaria.
